Assessing the Effects of HbA1c Reduction on Alleviating Nonspecific Back Pain

• Status: Completed
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Prediabetes, characterized by elevated HbA1c levels, is a common precursor to type 2 diabetes mellitus. Recent studies have suggested a potential link between prediabetes and nonspecific back pain. This randomized controlled trial aimed to assess whether reducing HbA1c levels through lifestyle interventions and, along with the correction of vitamin D and magnesium, can alleviate nonspecific back pain in prediabetic patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Baghdad

Criteria

Inclusion Criteria:

• Poor sleep (less than 6 hours per day)

• chronic back pain

• Multiple joint pain

• non-specific back pain

• HBA1C more than 5.7

• ability to record the data

Exclusion Criteria:

• Not able to record data

• previous spine surgeries

• severe OA in knee

• Spinal stenosis

• Peripheral vascular diseases

• Rheumatological diseases

• Lumbar disc prolapse

• uncooperative patient